<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048086/bin/gr2.jpg"/> </div> <div class="text-side"> <h1>Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines.</h1> <p>Hematoxylin &amp; eosin stain, PD-L1 immunohistochemical stain. (A) H&amp;E: Hematoxylin and eosin stain of patientâ€™s vulvar squamous cell carcinoma; (B) PD-L1: Programmed death ligand 1 immunohistochemistry of the same tumor sample.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35496740/" target="_blank">35496740</a></p><p>Type: Premalignant/Malignant, Category: Keratinocytic</p>
</div> </div></div></body></html>